Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161688 · ClinicalTrials.gov registry record · Phase 2
Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID
A Phase 2 study of Long COVID and Post Acute Sequelae of COVID-19, sponsored by Timothy Henrich.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06161688: Active Phase 2 study of Long COVID and Post Acute Sequelae of COVID-19, sponsored by Timothy Henrich.
NCT06161688 is a Phase 2 study of Long COVID and Post Acute Sequelae of COVID-19 that is active but no longer recruiting, run by Timothy Henrich. The registered enrollment target is 40 participants, below the 2,187-participant average among 50 other Long COVID trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06161688, a Phase 2 study of Long COVID and Post Acute Sequelae of COVID-19, is active but no longer recruiting, sponsored by Timothy Henrich.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be susceptible to antiviral therapy that blocks viral replication, which has the potential to alleviate long COVID symptoms. This trial will study the safety and efficacy of Ensitrelvir (S-217622), an antiviral, to treat individuals with Long COVID in an adult population.
Primary Outcome
This measure will evaluate whether there is a difference between treatment with Ensitrelvir versus placebo in baseline adjusted mean PROMIS-29 Physical Health Summary Score at 10 post-\[ADD\]. PROMIS-29 is a validated scale assessing physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social activities, and pain. Each domain is scored on a 5-point scale (without any difficulty, with a little difficulty, with some difficulty, with much difficulty, unable
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Ensitrelvir
Study Locations (1)
California
- UCSF/Zuckerberg San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-04-09 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What the registry record for NCT06161688 still lists
NCT06161688 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 2,187-participant average among 50 other Long COVID trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Long COVID appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06161688 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06161688 about?
NCT06161688 is a clinical study titled "Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID". Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be susceptible to antiviral therapy that blocks viral replication, which has the potential to alleviate...
What is the current status of trial NCT06161688?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-04-09. Estimated completion is 2025-12-31.
What conditions does trial NCT06161688 study?
This clinical trial studies the following conditions: Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19.
What interventions are being tested in trial NCT06161688?
The interventions under investigation include: Placebo (OTHER), Ensitrelvir (DRUG).
Who is sponsoring clinical trial NCT06161688?
This trial is sponsored by Timothy Henrich, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06161688 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06161688's enrollment target sits among peer trials
40 38th of 50 higher than 11 of 50 other Long COVID trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Long COVID trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NE3107 in Adults With Neurological Symptoms of Long COVID
RECRUITING · Phase 2
-
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)
RECRUITING · Phase 2
-
Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation
RECRUITING · Phase 2
-
AT1001 for the Treatment of Long COVID
RECRUITING · Phase 2
-
LIFT: Life Improvement Trial
RECRUITING · Phase 2
-
A Study to Examine Anktiva for the Treatment of COVID-19.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI